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Association between in vivo bone formation
and ex vivo migratory capacity of human bone
marrow stromal cells
Rikke K. Andersen1†, Walid Zaher1,2†, Kenneth H. Larsen1, Nicholas Ditzel1, Katharina Drews3, Wasco Wruck4,
James Adjaye3,4, Basem M. Abdallah1,5* and Moustapha Kassem1,2,6
Abstract
Introduction: There is a clinical need for developing systemic transplantation protocols for use of human skeletal
stem cells (also known bone marrow stromal stem cells) (hBMSC) in tissue regeneration. In systemic transplantation
studies, only a limited number of hBMSC home to injured tissues suggesting that only a subpopulation of hBMSC
possesses “homing” capacity. Thus, we tested the hypothesis that a subpopulation of hBMSC defined by ability to
form heterotopic bone in vivo, is capable of homing to injured bone.
Methods: We tested ex vivo and in vivo homing capacity of a number of clonal cell populations derived from
telomerized hBMSC (hBMSC-TERT) with variable ability to form heterotopic bone when implanted subcutaneously
in immune deficient mice. In vitro transwell migration assay was used and the in vivo homing ability of transplanted
hBMSC to bone fractures in mice was visualized by bioluminescence imaging (BLI). In order to identify the
molecular phenotype associated with enhanced migration, we carried out comparative DNA microarray analysis of
gene expression of hBMSC-derived high bone forming (HBF) clones versus low bone forming (LBF) clones.
Results: HBF clones were exhibited higher ex vivo transwell migration and following intravenous injection, better in
vivo homing ability to bone fracture when compared to LBF clones. Comparative microarray analysis of HBF versus
LBF clones identified enrichment of gene categories of chemo-attraction, adhesion and migration associated genes.
Among these, platelet-derived growth factor receptor (PDGFR) α and β were highly expressed in HBF clones. Follow
up studies showed that the chemoattractant effects of PDGF in vitro was more enhanced in HBF compared to LBF
clones and this effect was reduced in presence of a PDGFRβ-specific inhibitor: SU-16 f. Also, PDGF exerted greater
chemoattractant effect on PDGFRβ+ cells sorted from LBF clones compared to PDGFRβ- cells.
Conclusion: Our data demonstrate phenotypic and molecular association between in vivo bone forming ability and
migratory capacity of hBMSC. PDGFRβ can be used as a potential marker for the prospective selection of hBMSC
populations with high migration and bone formation capacities suitable for clinical trials for enhancing bone
regeneration.
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Introduction
Human skeletal stem cells (also known as human bone
marrow-derived stromal cells (hBMSC)) are adult multi-
potent stem cells located in the bone marrow perivascu-
lar niche and are recruited to bone formation sites
during bone remodeling [1]. During recent years,
hBMSC have been tested in a number of clinical trials
for their ability to enhance tissue repair including tissue
regeneration where hBMSC were injected locally at the
sites of tissue injury; for example, bone fracture [2–4] or
ischemic myocardium [5–8]. However, systemic intra-
venous infusion is more suitable for clinical cell trans-
plantation and is employed for hematopoietic stem cell
(HSC) transplantation with success and where HSCs,
following homing from systemic circulation to bone
marrow, engraft and initiate hematopoiesis [9].
Several studies have demonstrated that systemically
injected bone marrow-derived stromal cells (BMSC) can
home to damaged tissues in animal models of brain in-
jury [10], skeletal disorders [11–13], and acute radiation
syndrome [14, 15]. However, the number of BMSC that
home and engraft in injured tissues is usually small and
most of the infused BMSC get entrapped in the lungs
[16, 17]. The explanation for these phenomena is still
missing because the mechanisms governing migration of
BMSC to injured tissues are poorly understood [18].
Cultured hBMSC are a heterogeneous population of
cells that when analyzed at a clonal level exhibit varia-
tions in cell morphology, proliferation, and differenti-
ation capacity [19, 20]. Recently, we have also
demonstrated that clonal heterogeneity of the hBMSC
population reflects functional heterogeneity with re-
spect to cell capacity for osteoblast adipocyte differen-
tiation or immune functions [21, 22].
Here we hypothesized the existence of clonal hetero-
geneity in the ability of hBMSC to home to injured tis-
sues (e.g., bone fractures) and that hBMSC with good
bone-forming capacity will be more efficient at homing
to bone fracture sites. To test this hypothesis, we exam-
ined the ex vivo and in vivo migratory capacity of a
number of clonal cell populations isolated from telomer-
ized hBMSC that exhibit variation in their ability to form
heterotopic bone when implanted in vivo [21]. Our re-
sults demonstrate that there is phenotypic association
between the in vivo bone formation and migratory cap-
acity to bone fracture sites, and furthermore identified
platelet-derived growth factor receptor (PDGFR)α and
PDGFRβ as potential markers for the hBMSC popula-
tion with enhanced migratory function.
Methods
Human mesenchymal stem cell culture
As a model for primary hBMSC, we employed our
well-characterized telomerized hBMSC-TERT cell line,
established by ectopic expression of the catalytic subunit of
human telomerase as described previously [23]. The
hBMSC-TERT cells exhibit a stable cellular and molecular
phenotype during in vitro culture similar to that of primary
hBMSC [24]. The derivation and characterization of
hBMSC-TERT+Bone, hBMSC-TERT–Bone, and high bone-
forming (HBF) and low bone-forming (LBF) single-cell
clones have been described previously by our group [21].
In brief, the hBMSC-TERT+Bone subpopulation was derived
from early-passage hBMSC-TERT cells (population doub-
ling level 77), and showed high capacity for in vivo hetero-
topic bone formation, while the hBMSC-TERT–Bone
subpopulation was derived from hBMSC-TERT cells
(population doubling level 233), and showed LBF capacity.
Both the HBF and LBF single-cell clones were derived from
hBMSC-TERT+Bone cells by the limiting dilution method.
The cells were cultured in a standard growth medium
containing minimal essential medium (MEM) (Gibco,
Invitrogen, Herlev, Denmark) supplemented with 10 %
fetal calf serum (FCS) (Biochrom, Berlin, Germany) and
1 % penicillin/streptomycin (Gibco, Invitrogen, Herlev,
Denmark) at 37 °C in a humidified atmosphere containing
5 % CO2. The medium was changed every third day until
cells became 90 % confluent.
Studying cell spreading and focal adhesion formations
Cell culture plates were coated with fibronectin (10 μg/ml)
in phosphate-buffered saline (PBS) for 2 hours at 37 °C,
rinsed twice with PBS, and blocked with 1 % bovine serum
albumin (BSA) for 1 hour. Cells were trypsinized, washed
twice with MEM, and resuspended in serum-free medium
for 1 hour at room temperature. Cell were then replated
onto fibronectin-coated plates in standard culture
medium supplemented with platelet-derived growth
factor (PDGF)-BB (100 ng/ml) for 30 minutes at 37 °C.
Cells were fixed in 4 % paraformaldehyde for 10 minutes,
washed with PBS, and stained for F-actin with Phalloidin–
fluorescein isothiocyanate (FITC) (Sigma, Brøndby,
Denmark) and for focal adhesion with mouse monoclo-
nal anti-Vinculin antibody (Sigma, Brøndby, Denmark)
using Alexa Fluor® 488-conjugated rabbit anti-mouse
IgG (H + L) as secondary antibody (Cell Signaling).
Fluorescent staining was visualized by the Operetta®
High Content Imaging system (Perkin Elmer, Rodgau,
Germany) at 20× magnification. Fluorescent images
were analyzed using Harmony® High Content Imaging
Analysis Software (Perkin Elmer, Rodgau, Germany).
Microarray analysis
Microarray analysis was performed on hBMSC-TERT+Bone,
hBMSC-TERT–Bone, and hBMSC-TERT-derived single-
cell clones: HBF (three clones; DD8, AD10, BB10) and
LBF (three clones; CF1, CB4, CB8). To perform global
gene expression analysis, 500 ng quality-checked total
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RNA per sample in triplicate were amplified and
labeled according to the manufacturer’s protocol
(Illumina TotalPrep RNA Amplification Kit; Ambion,
Austin, TX, USA [25]). The resulting biotinylated
cRNA was purified and hybridized to Illumina
HumanRef-8 v3 Expression BeadChips (Illumina, San
Diego, CA, USA [26]) on the Illumina Beadstation
500 platform. This was followed by washing, block-
ing, staining with streptavidin-Cy3, and quantitative
detection of the fluorescent image of the array as
specified by the manufacturer.
Raw data were processed using the Gene Expression
Module version 1.8.0 provided with the GenomeStudio
software (Illumina). This included background subtrac-
tion and normalization according to the “rank invariant”
algorithm. Genes were considered “expressed” if the
corresponding “Detection P-Value” given by the Geno-
meStudio software was pdet <0.01. Differential gene ex-
pression analysis was computed using the Illumina
Custom Model. p values of differentially expressed
genes (“Diff P-Values”) were modified by the Benjamini
and Hochberg false discovery rate (FDR) correction al-
gorithm [27]. Genes were considered differentially
expressed genes if: they exhibited twofold upregulation
or downregulation in average signal intensity; the corre-
sponding FDR-adjusted “Diff P-Value” was padj <0.05; or
the gene of interest was expressed in at least one of the
samples under consideration.
Differentially upregulated genes in group 1 (hBMSC-
TERT+Bone and three HBF clones) when compared with
group 2 (hBMSC-TERT–Bone and three LBF clones) are
presented in Table 1.
Functional annotation and identification of enriched
biological categories were carried out using DAVID plat-
form version 6.7 [28–30].
The microarray data have been deposited in the public
repository [GEO:GSE69358].
Total RNA isolation and real-time PCR
RNA was isolated from cultured cells using Trizol® (Bio-
Rad, Herlev, Denmark) according to the manufacturer’s
protocol. cDNA was synthesized using a commercial
revertAid H minus first strand cDNA synthesis kit (Fer-
mentas, Copenhagen, Denmark) according to the instruc-
tion manual. Real-time PCR was performed in the iCycler
IQ detection system (Bio-Rad, Herlev, Denmark) using
SYBR® Green I as described previously [24]. Primer se-
quences are indicated in Table S1 in Additional file 1. The
expression level for each target gene was calculated using
the comparative Ct formula 1/(2ΔCt) and data were pre-
sented as relative expression to the reference genes (RG)
(HPRT1 and UBC). Data were analyzed using Microsoft
Excel 2000 to generate relative expression values.
Flow cytometry analysis
Cells were trypsinized and washed with PBS containing
0.5 % BSA (Fluorescence Activated Cell Sorting (FACS)
buffer) and 50 μg/ml trypsin inhibitor. Cells were then
incubated with primary antibody for PDGFRβ
(0.025 mg/ml, PR292a; R&D Systems (Abingdon, UK)
diluted 1:50 in FACS buffer for 30 minutes on ice. The
cells were washed twice with ice-cold FACS buffer and
incubated with FITC-conjugated goat anti-mouse anti-
body (R&D Systems) for 30 minutes on ice. The cells
were analyzed by flow cytometer Cell Lab Quanta
TMSC (Beckman Coulter using Kaluza version1.2
(Beckman Coulter, Copenhagen, Denmark).
Magnetic activated cell sorting of hBMSC-TERT–Bone
Cells were rinsed with PBS, lifted with trypsin, and di-
luted in Magnetic activated cell sorting (MACS) buffer
(PBS with 0.5 % (w/v) BSA and 2 mM ethylenediamine
tetraacetic acid (EDTA)) before incubation with
PDGFRβ antibody (R&D Systems) for 20 minutes at 4 °
C. Cells were washed with MACS buffer, incubated with
anti-mouse-beads (Miltenyi Biotec, Lund, Sweden) for
15 minutes at 4 °C, and run through a MS column (Mil-
tenyi Biotec, Lund, Sweden) according to the manufac-
turer’s instructions.
Generating the Luciferase-overexpressing hBMSC-TERT
+Bone and hBMSC-TERT–Bone
The hBMSC-TERT+Bone and hBMSC-TERT–Bone cells
were transduced with a retroviral vector containing the
firefly luciferase gene (Luc2) producing luciferase-
containing hBMSC-TERT (hBMSC-TERT-Luc). The lucif-
erase reporter gene luc2 (Photinus pyralis) was subcloned
into the retroviral vector pBABE-puro (addgene Plasmid
1764). Retroviral vector was transfected into the Phoenix-
AMPHO packaging cells (CRL-3213™; ATCC), and cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM)
medium (Gibco, Invitrogen, Herlev, Denmark) supple-
mented with 10 % FCS until 70–80 % confluent, using the
FuGENE 6 (Roche, Hvidovre, Denmark) reagent according
to the manufacturer’s instruction. For cell transduction,
the supernatants collected from Phoenix packaging cells
containing virus particles were filtered with a 0.45 μm fil-
ter and added to hBMSC-TERT cell lines in the presence
of Polybrene (Sigma, Brøndby, Denmark). Stably trans-
duced cells were selected on the antibiotic puromycine.
In vitro differentiation studies and cytochemical staining
Osteoblast differentiation
Cells were plated at 2 × 104 cells/cm2 in six-well plates
in modified Dulbecco medium (MEM) (GIBCO, Herlev,
Denmark) containing 10 % fetal bovine serum (FBS)
(GIBCO), 100 U/ml penicillin (GIBCO), and 100 μg/ml
streptomycin (GIBCO). One day after plating, media
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Table 1 Genes differentially upregulated in HBF clones + hBMSC-TERT+Bone versus LBF clones + hBMSC-TERT–Bone
Category PROBE_ID Gene
symbol
Gene name Fold
change
p value Gene function
Migration ILMN_1798360 CXCR7 Chemokine (C-X-C motif)
receptor 7
30.34323 1.57 × 10–5 Receptor for CXCL12/SDF1
ILMN_1689111 CXCL12 Chemokine (C-X-C motif)
ligand 12
7.64381 6.57 × 10–5 Activates the C-X-C chemokine receptor CXCR4 to
induce a rapid and transient rise in the level of
intracellular calcium ions and chemotaxis
ILMN_2373791 ENPP2 Ectonucleotide
pyrophosphatase/
phosphodiesterase 2
6.481839 1.58 × 10–13 Leukocyte-endothelial cell adhesion
ILMN_1722713 FBLN1 Fibulin 1 5.060076 8.1 × 10–17 Plays a role in cell adhesion and migration
ILMN_2082585 SNAI2 Snail homolog 2 4.84552 3.28 × 10–25 Involved in the generation and migration of
neural crest cells
ILMN_1811313 SLIT3 Slit homolog 3 4.378596 1.14 × 10–15 Acts as molecular guidance cue in cellular
migration
ILMN_1802646 EPHB6 EPH receptor B6 4.171862 0.00022 Modulates cell adhesion and migration
ILMN_2086470 PDGFRA Platelet-derived growth factor
receptor, alpha polypeptide
4.168592 0.009945 Receptor that binds both PDGFA and PDGFB
ILMN_2339266 LAMA2 Laminin, alpha 2 3.959818 5.47 × 10–6 Mediates the attachment, migration, and
organization of cells into tissues during embryonic
development
ILMN_2307903 VCAM1 Vascular cell adhesion
molecule 1
3.080952 7.75 × 10–5 Plays a role in leukocyte endothelial cell adhesion
ILMN_1757338 PLSCR4 Phospholipid scramblase 4 2.885336 0.008172 Mediates bidirectional transbilayer migration of
phospholipids, plays a central role in the initiation
of fibrin clot formation and activation of mast
cells and in the recognition of apoptotic and
injured cells
ILMN_1761540 SEMA3F Sema domain,
immunoglobulin domain (Ig),
short basic domain, secreted,
(semaphorin) 3 F
2.657031 8.68 × 10–8 Plays a role in cell motility and cell adhesion
ILMN_1659306 SVIL Supervillin 2.569266 0.001237 May modulate myosin II regulation through MLCK
during cell spreading, an initial step in cell
migration
ILMN_1667893 TNS3 Tensin 3 2.446932 5.1 × 10–6 Involved in cell migration and bone development
ILMN_1815057 PDGFRB Platelet-derived growth factor
receptor
2.147921 5.33 × 10–10 Receptor that binds both PDGF-AA and PDGF-BB
Adhesion ILMN_2408683 PPAP2B Phosphatidic acid phosphatase
type 2B
8.923443 4.45 × 10–11 May be involved in cell adhesion and in cell–cell
interactions
ILMN_1684554 COL16A1 Collagen, type XVI, alpha 1 3.998721 4.96 × 10–12 Involved in mediating cell attachment and
induction of integrin-mediated cellular reactions,
such as cell spreading and alterations in cell
morphology
ILMN_1801246 IFITM1 Interferon induced
transmembrane protein 1 (9–27)
3.467308 1.36 × 10–14 Component of a complex involved in adhesion
signals
ILMN_2396444 CD14 CD14 molecule 3.169754 0.000265 Upregulates cell surface molecules, including
adhesion molecules
ILMN_2307903 VCAM1 Vascular cell adhesion
molecule 1
3.080952 7.75 × 10–5 Plays a role in leukocyte endothelial cell adhesion
ILMN_2229877 PCDH18 Protocadherin 18 2.939445 6.56 × 10–8 Potential calcium-dependent cell-adhesion protein
ILMN_1761540 SEMA3F Sema domain,
immunoglobulin domain (Ig),
short basic domain, secreted
2.657031 8.68 × 10–8 May play a role in cell motility and cell adhesion
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were replaced with osteogenic media including culture
media supplemented with 10 mM β-glycerophosphate
(Sigma, Brøndby, Denmark), 10 nM dexamethasone
(Sigma, Brøndby, Denmark), 10 nM Calcitriol (1,25-
dihydroxyvitamin D3; Leo, Ballerup, Denmark), and
50 μg/ml vitamin C (Sigma, Brøndby, Denmark). The
osteogenic medium was changed every other day for
2 weeks.
Adipocyte differentiation
For adipocyte differentiation, cells were plated at 3 × 104
cells/cm2 in six-well plates in culture media. The day
after, culture media was removed and adipogenic
media was added including MEM (GIBCO), 10 % FBS
(GIBCO), 10 % horse serum (GIBCO), 100 U/ml
penicillin (GIBCO), 100 μg/ml streptomycin (GIBCO),
100 nM dexamethasone (Sigma, Brøndby, Denmark),
0.25 mM 3-isobutyl-1-methylxanthine (IBMX, Gibco,
Herlev, Denmark), 1 μM BRL (Rosiglitazone; Sigma,
Brøndby, Denmark), and 500 nM insulin (Sigma,
Brøndby, Denmark,). The adipogenic medium was
changed every other day for 20 days.
Alkaline phosphatase staining
At 7 and 14 days during osteoblast differentiation, cells
were fixed with acetone/citrate (10 mM) buffer, pH 4.2
Table 1 Genes differentially upregulated in HBF clones + hBMSC-TERT+Bone versus LBF clones + hBMSC-TERT–Bone (Continued)
ILMN_1812461 WISP2 WNT1 inducible signaling
pathway protein 2
2.336378 0.001181 Promotes the adhesion of osteoblast cells and
inhibits the binding of fibrinogen to integrin
receptors
ILMN_1769575 JAM3 Junctional adhesion molecule 3 2.195171 4.39 × 10–5 May participate in cell–cell adhesion
ILMN_2223941 FBLN5 Fibulin 5 2.099419 0.000119 Promotes adhesion of endothelial cells through
interaction of integrins
ILMN_2115125 CTGF Connective tissue growth
factor
2.037551 3 × 10–9 Mediates heparin-dependent and divalent
cation-dependent cell adhesion
ILMN_1707070 PCOLCE Procollagen C-endopeptidase
enhancer
2.023961 1.28 × 10–5 Procollagen C-endopeptidase enhancer
Bone
formation
ILMN_1696391 LEPR Leptin receptor 9.88173 0.000244 Leptin receptor
ILMN_1690945 CPZ Carboxypeptidase Z 6.636527 2.46 × 10–11 Modulates the Wnt signaling pathway
ILMN_1800317 WNT5A Wingless-type MMTV
integration site family,
member 5A
4.39779 5.65 × 10–6 Can activate or inhibit canonical Wnt signaling
ILMN_1709734 BMP4 Bone morphogenetic protein 4 3.425185 0.003465 Induces cartilage and bone formation
ILMN_1758895 CTSK Cathepsin K (CTSK), mRNA. 2.655974 0.000136 Closely involved in osteoclastic bone resorption
ILMN_1684755 KAZALD1 Kazal-type serine peptidase
inhibitor domain 1
2.583283 0.001055 Involved in the proliferation of osteoblasts during
bone formation and bone regeneration
ILMN_1724480 AXIN2 Axin 2 2.432503 5.5 × 10–7 Downregulates beta-catenin
ILMN_1770161 BST1 Bone marrow stromal cell
antigen 1
2.417137 0.002254 Involved in osteoclastic bone resorption
ILMN_1729368 FZD8 Frizzled homolog 8 2.013491 0.005335 Receptor for Wnt proteins
Cytoskeletal ILMN_1812031 PALM Paralemmin 9.661952 0.004851 Control of cell shape
ILMN_1780334 KCNJ2 Potassium inwardly-rectifying
channel, subfamily J, member 2
9.409812 1.23 × 10–21 Participates in establishing action potential
waveform and excitability of neuronal and muscle
tissues
ILMN_1654319 HAPLN3 Hyaluronan and proteoglycan
link protein 3
6.178261 3.95 × 10–27 May function in hyaluronic acid binding
ILMN_1741695 COL12A1 Collagen, type XII, alpha 1 2.071144 0.008916
ILMN_1670899 FBN2 Fibrillin 2 2.065329 0.000762 Contains microfibrils that regulate the early
process of elastic fiber assembly
ILMN_1674620 SGCE Sarcoglycan, epsilon 2.034948 7.35 × 10–6 A subcomplex of the dystrophin–glycoprotein
complex which forms a link between the F-actin
cytoskeleton and the extracellular matrix
ILMN_1780334 KCNJ2 Potassium inwardly-rectifying
channel, subfamily J, member
2
9.409812 1.23 × 10–21 Participates in establishing action potential
waveform and excitability of neuronal and muscle
tissues
HBF high bone forming, hBMSC human bone marrow-derived stromal cells, LBF low bone forming, PDGF platelet-derived growth factor
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(1.5:1), for 5 minutes at room temperature and stained
with the 1:1 mixture of 0.2 mg/ml Napthol-AS-TR-phos-
phate (Sigma) and 1.3 mg/ml Fast Red TR solution
(Sigma) in 0.1 M Tris buffer, pH 9.0, for 1 hour at room
temperature.
Alizarin Red staining
Alizarin Red staining was performed on days 7 and 14 of
osteoblast differentiation to assess matrix mineralization
of osteoblastic cultures. Cells were fixed with 70 % ice-
cold ethanol for 1 hour at −20 °C, and stained with
40 mM Alizarin Red S (AR-S; Sigma, Brøndby, Denmark),
pH 4.2, for 10 minutes at room temperature. The amount
of mineralized matrix (bound stain) was quantified by
eluting the Alizarin Red stain, using 20-minute incubation
of the cultures in 10 % (w/vol) cetylpyridinium chloride
solution. The absorbance of the eluted stain was measured
at 570 nm using FLUOstar Omega multimode microplate
reader (Leica, Ballerup, Denmark).
Oil Red O staining
Adipocytic cultures from days 10 and 20 were fixed with
4 % paraformaldehyde for 10 minutes at room temperature,
rinsed with 3 % isopropanol solution, and stained with
Oil Red O (Sigma, USA) solution for 1 hour at room
temperature. Oil Red O solution consist of 25 mg Oil
Red O dye, 5 ml of 60 % isopropanol, and 3.35 ml
H2O. The bound dye was eluted by 100 % isopropanol
and absorbance measured at 490 nm using FLUOstar
Omega multimode microplate reader.
Microscopy
Images were taken using a Leica® DM4500B microscope
equipped with a motorized stage (Märzhäuser Wetzlar
GmbH, Wetzlar, Germany) and a Leica® DFC300 FX cam-
era. Images were acquired with the Surveyor® software
(Objective Imaging, Leica, Ballerup, Denmark).
Boyden chamber transwell migration assay
For migration experiments, 90 % confluent cells were
starved for 24 hours in low-glucose Dulbecco’s minimal
essential medium (LG-DMEM; GIBCO, Herlev, Denmark)
supplemented with 0.1 % (w/v) BSA (Sigma, Brøndby,
Denmark), harvested, and assayed using the AP48 Migra-
tion Assay system and 8 μm pore size polycarbonate mem-
branes (NeuroProbe, Inc., USA). Membranes were coated
for 1 hour at 37 °C with 5 μg/ml fibronectin (human pla-
centa; Sigma) and 10 μg/ml rat tail collagen type I (Sigma,
Brøndby, Denmark) in migration media consisting of LG-
DMEM (GIBCO) supplemented with 0.2 % FBS (GIBCO).
hBMSC-TERT cells in LG-DMEM with 0.1 % BSA (con-
trol medium) with or without pretreatment (see later) were
added to the wells. Control media with or without PDGFs
were added to the lower chamber. The assembled assay
was incubated at 37 °C for 4 hours. After removal of cells
on the upper side of the membrane with a rubber scraper,
cell migration through the membrane was quantitated by
staining cells with the Hemacolor staining kit (Merck),
and cells were counted from one picture/well taken at
10× magnification by a computer-assisted cell-counting
program (Visiopharm, Hørsholm, Denmark). The fol-
lowing concentrations of factors were used: PDGF-BB
(PeproTech GmbH Hamburg, Germany), 10–100 ng/
ml; PDGF-AA (PeproTech GmbH Hamburg, Germany),
100 ng/ml; PDGF-AB (PeproTech GmbH Hamburg,
Germany), 100 ng/ml; and PDGFRβ inhibitor (SU16f;
Tocris), 10–200 nM. Then 1 μl/ml vehicle (dimethyl
sulfoxide (DMSO)) were added to the cells just prior to
assay assembly.
In vivo homing studies
Animals
Ethical permission for animal study was granted from
the Danish National Authority on animal experiments
(2012-15-2934-00559). Immunodeficient NOD scid
(NOD.CB17-Prkdcscid/J) mice were used and operations
were performed under intraperitoneal injection of ketamine
(100 mg/kg) and xylazine (10 mg/kg). Temgesic (100 mg/
kg) was given subcutaneously every 8 hours to relieve
postoperative pain for at least 3 days post procedure.
Closed femur fracture
The closed femur fracture procedure was carried out as
described by Bonnarens and Einhorn [31]. In brief, an
incision was made just medial to the patella, and then
the longitudinal fibers of the quadriceps were divided
and the patella dislocated laterally exposing the femur
condyles. A 0.5 mm needle was inserted between the
condyles and drilled in a retrograde fashion into the me-
dullary cavity of the femur (functioning as a nail fixating
the fracture). Afterwards, a standardized reproducible
closed fracture was induced using a guillotine fracture
apparatus [31]. A radiograph was acquired following
fracture induction (using Faxitron MX-20; Faxitron X-
Ray , Lincolnshire, USA) to confirm the fracture induc-
tion and needle position.
Transplantation studies and bioluminescence imaging
Immunodeficient NOD/SCID (NOD/LtSz/Prkdcscid/J)
12-week-old female mice (n = 24) were randomly divided
into the two main fracture study groups. The hBMSC-
TERT+Bone (n = 12) or hBMSC-TERT–Bone cells (n = 12)
were injected intravenously via tail vein at a dose of 1 ×
106 cells/mouse suspended in 200 μl PBS per injection.
For noninvasive imaging analysis, mice were injected
with D-Luciferin (150 mg/kg, intraperitoneal injection;
Caliber Life Sciences), and after 10 minutes the mice
were placed in a supine position for image acquisition
Andersen et al. Stem Cell Research & Therapy  (2015) 6:196 Page 6 of 14
with 5 minutes of acquisition time using the IVIS Im-
aging System, 200 Series (Xenogen Corp., Rodgau,
Germany). Bioluminescence color images were overlaid
on gray-scale photographic images of the mice to allow
for localization of the light source using the Livingimage™
software (V. 2.11) overlay (Xenogen Corp., Rodgau,
Germany). To equalize comparisons across animals and
between groups, the scales were fixed. Regions of interest
(ROI) were manually selected, and signal intensity was
expressed in terms of number of photons/cm2/second.
Statistical analysis
Data are presented as mean ± standard error of the mean
SEM. Statistical analysis was performed using unpaired,
two-tailed Student’s t test for comparison between two
groups and one-way analysis of variance for comparison
between more than two groups using Graphpad Prism ver-
sion 5.0 software (Graphpad Prism Software, Inc., La Jolla,
CA, USA). For all experiments, p <0.05 compared with
control was considered significant.
Results
hBMSC-TERT+Bone cells demonstrate high ex vivo directed
migratory function
To study whether the ability to form heterotopic bone in
vivo is associated with an enhancement of the migratory
capacity of hBMSC, we compared the ex vivo transwell
migration ability of two populations derived from hBMSC-
TERT cells: one capable of in vivo bone formation
(hBMSC-TERT+Bone) versus one that lacks this ability
(hBMSC-TERT–Bone) [21]. As shown in Fig. 1a, the trans-
well migration ability of hBMSC-TERT+Bone toward
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of control condition (without chemoattractant). Photomicrographs represent stained migrated cells. b Cytoskeletal changes in hBMSC-TERT+Bone
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PDGF-BB was significantly higher compared with
hBMSC-TERT–Bone.
hBMSC-TERT+Bone cells exhibit distinct cytoskeletal
properties
Since cell migration includes a cascade of cellular events
of cell spreading and focal adhesion formation [32], we
compared cytoskeletal and adhesion properties of
hBMSC-TERT+Bone versus hBMSC-TERT–Bone when cul-
tured on fibronectin-coated plates for 2 hours and stained
for F-actin and vinculin. As shown in Fig. 1b, hBMSC-
TERT+Bone exhibited more cells spreading with formation
of cytoskeletal projections, increased mean cell area, and
reduced mean cell roundness. In addition, the focal adhe-
sion number per cell area, as visualized by vinculin stain-
ing, was increased in hBMSC-TERT+Bone (Fig. 1b).
hBMSC-TERT+Bone cells exhibit enhanced in vivo homing
to fractured bone site
We further compared the in vivo homing ability of
hBMSC-TERT+Bone versus hBMSC-TERT–Bone to bone
fracture sites in mice. hBMSC-TERT+Bone and hBMSC-
TERT–Bone were stably transduced with a retroviral vector
expressing the luciferase gene 2 (Luc2). Luc-overexpressing
cell lines exhibited high levels of luciferase enzyme activity
and maintained their differentiation capacity similar to the
parental cell lines (Figure S1a, b in Additional file 1).
hBMSC-TERT-Luc+Bone and hBMSC-TERT-Luc–Bone were
administrated intravenously via tail vein injection in
SCID/NOD mice with a stabilized femur bone fracture
immediately following fracture induction. Noninvasive
bioluminescence imaging using the IVIS Imaging System
showed trapping of both cell lines in the lungs after 1 day
(Fig. 1c). hBMSC-TERT+Bone cells and not hBMSC-
TERT–Bone, were able to migrate to the fracture sites by
day 6 (Fig. 1c).
Molecular phenotype of hBMSC single-cell clones with
enhanced migratory function
Since hBMSC-TERT+Bone and hBMSC-TERT–Bone are
nonclonal populations, we further studied the migratory
capacity of three hBMSC-TERT-derived single-cell
clones with either HBF capacity (HBF1, HBF2, and
HBF3) or three cell clones with LBF capacity (LBF1,
LBF2, and LBF3) [21]. HBF clones showed higher migra-
tory capacity toward PDGF-BB as compared with LBF
clones, supporting our hypothesis of the existence of an
association between the in vivo bone formation capacity
and ex vivo migratory capacity of hBMSC (Fig. 2a).
To identify the molecular signature underlying en-
hanced hBMSC migratory function, we performed a
global DNA microarray analysis comparing the tran-
scriptome profile of hBMSC-TERT+Bone, hBMSC-
TERT–Bone, the three HBF clones (HBF1, HBF2, and
HBF3), and the three LBF clones (LBF1, LBF2, and
LBF3). Cluster analysis revealed molecular clustering
of HBF clones to hBMSC-TERT+Bone and LBF clones to
hBMSC-TERT–Bone (Fig. 2b). We identified 427 genes
(cutoff level ≥2-fold, p 0.05) that are upregulated in
hBMSC-TERT+Bone and HBF clones compared with
hBMSC-TERT–Bone and LBF clones (Table S2 in
Additional file 1). Gene annotation analysis based on mo-
lecular functions revealed significant enrichment of gene
categories of cell migration (12 %), cell adhesion (17 %),
cytoskeletal genes (12 %), and bone-related genes (16 %)
in hBMSC-TERT+Bone and HBF clones (Fig. 2c, Table 1).
Some of the significantly upregulated genes by HBF clones
were confirmed by real-time RT-PCR (Fig. 2d).
PDGFRα and PDGFRβ are associated with enhanced
hBMSC migration
To identify surface marker(s) that can be used pro-
spectively to isolate the hBMSC population with enhanced
migratory functions, we examined differentially expressed
genes in HBF clones. Both PDGFRα (CD140A) and
PDGFRβ (CD140B) were found to be significantly upregu-
lated by hBMSC-TERT+Bone and HBF clones versus
hBMSC-TERT–Bone and LBF clones by 4.16-fold and
2.14-fold respectively (Table 1). These data have also been
confirmed by quantitative RT-PCR analysis (Fig. 3a, b).
To test for the specific contribution of PDGFRs to mi-
gratory functions, we tested the effect of PDGF and
other growth factors known to exert chemoattractant
function: insulin-like growth factor 1 (IGF1), stromal
cell-derived factor 1 (SDF1), and tumor necrosis factor
alpha (TNFα). The ex vivo transwell migratory capacity
of hBMSC-TERT+Bone was significantly higher toward
PDGF-BB compared with other chemoattractants
(Fig. 4a). We next confirmed the specificity of chemotac-
tic effects of PDGF isoforms on hBMSC-TERT+Bone. As
shown in Fig. 4b, hBMSC-TERT+Bone exhibited higher
migration toward heterodimeric PDGF-AB or homodi-
meric PDGF-AA and PDGF-BB proteins and their mi-
gration was decreased by adding the same concentration
of PDGF isoform to both lower and upper chambers
in the transwell migration assay (Fig. 4b). Further-
more, we demonstrated a dose-dependent stimulatory
effect of PDGF-BB on increasing the migration of
hBMSC-TERT+Bone versus hBMSC-TERT–Bone (Fig. 4c).
In addition, selective inhibition of PDGFRβ signaling
in hBMSC-TERT+Bone using the chemical inhibitor SU-16f
suppressed the migration of hBMSC-TERT+Bone toward
PDGF-BB in a dose-dependent manner (Fig. 4d).
Identifying PDGFRβ as a marker for prospective isolation
of a population of hBMSC with migratory function
To study the possible use of PDGFRβ as a candidate
marker for isolating hBMSC with increased migratory
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capacity, MACS-enriched PDGFRβ+ cells from hBMSC-
TERT–Bone (Fig. 5a) were obtained and the PDGFRβ+
cells were examined for their response to PDGF iso-
forms in the transwell migration assay. Sorted PDGFRβ+
cells exhibited enhanced chemotactic migration toward
different PDGF isoforms as compared with the PDGFRβ-
negative population (Fig. 5b).
Discussion
In the present study, we demonstrate that a subpopula-
tion of hBMSC with known ability to form bone in vivo
exhibits enhanced ability to migrate in vitro and to home
to bone fractures in vivo. In addition, we identified a
molecular signature that defines this population and one
surface marker, PDGFRβ (CD 140b), that can be
employed for prospective isolation of the cells with en-
hanced migratory capacity from heterogeneous hBMSC
cultures.
hBMSC are capable of multilineage differentiation into
various mesoderm-type cells including osteoblastic cells
[33], which is the basis for their use in cell-based therap-
ies for bone tissue regeneration; for example, in repair of
bone defects and nonhealed fractures [34–36]. However,
cultured hBMSC represent a heterogeneous population
with respect to differentiation capacity (so-called pro-
genitor functions) as well as nonprogenitor functions.
For example, not all hBMSC maintained under standard
culture conditions are capable of bone formation [19].
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Fig. 2 Transcriptional upregulation of the migratory-related factors by hBMSC with high bone formation capacity. a The transwell migration ability
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Similarly, when hBMSC are infused intravenously, only a
small population of cells home to injured tissue [37].
The efficient use of hBMSC in therapy thus requires de-
fining an ex vivo molecular phenotype predictive for the
in vivo behavior [21]. In the present study, we have in-
vestigated the correlation between two characteristics:
cellular migratory behavior and ability to form hetero-
topic bone, as well as homing capacity to bone fractures
in vivo. For this purpose, we employed previously char-
acterized hBMSC clones with various capacities for
in vivo heterotopic bone formation. Our data suggest
that in vivo heterotopic bone formation capacity is asso-
ciated with enhanced in vivo migratory abilities to bone
fractures.
By comparing the transcriptome profile of hBMSC-
TERT+Bone and hBMSC-TERT–Bone and clones with dif-
ferent heterotopic bone-forming capacities, we identified
a molecular signature linking homing and in vivo bone
formation potential. This molecular signature included
expression of high levels of known genes important for
cell migration and homing. Among these were chemo-
kine (C-X-C motif ) receptor 7 (CXCR7) and chemokine
(C-X-C motif ) ligand 12 (CXCL12) [38], extracellular
matrix, and adhesion molecules (e.g., collagen, type XVI,
alpha 1 (COL16A1) and vascular cell adhesion molecule
1 (VCAM-1)) [39].
We have demonstrated that hBMSC with bone-
forming capacity can home to bone fracture, suggesting
that these migratory cells are recruited from the circula-
tion under physiological conditions of bone formation
and bone regeneration. However, the contribution of
homed hBMSC to bone regeneration at bone fracture
sites has been a contentious issue [40]. Some studies
have demonstrated that circulating hBMSC can home
and contribute to fracture healing [36, 41, 42]. Also,
patients with recent fractures have a large number of
circulating osteoprogenitor (i.e., hBMSC-like) cells in
their peripheral circulation, providing circumstantial
evidence of recruiting bone-forming cells to bone frac-
ture sites [43]. On the other hand, some studies have
demonstrated that the contribution of homed hBMSC
to bone fracture healing is limited and that fracture
healing is mediated by locally recruited cells possibly from
periosteum or bone marrow [44, 45]. Our study suggests
that there exists a population of hBMSC with enhanced
bone-forming and migratory capacity. Further prospective
studies are needed to quantitate the contribution of this
cell population to fracture healing and bone regeneration.
Some of the molecules identified in the molecular
signature defining high bone formation and migratory
capacity do not seem to contribute to the migratory
phenotype. For example, CXCR7 expression was
highly upregulated in cells with HBF capacity, but we
were unable to detect an increased ex vivo chemotac-
tic migration toward its ligand SDF-1. It is possible
that other noncanonical receptors are involved in
regulating the migratory function of hBMSC. It is
also plausible that hBMSC differ from leucocytes re-
garding the molecules employed for transendothelial
migration. In support of this notion, we did not
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detect increased homing of hBMSC to bone fracture
in vivo in hBMSC overexpressing CXCR4 (data not
shown), a known factor enhancing leukocyte and HSC
homing [46].
We identified high expression levels of PDGFRα and
PDGFRβ to be associated with enhanced chemotactic
migration of hBMSC toward PDGF isoforms. Therefore,
PDGFRβ can be used as a possible marker to enrich for
hBMSC with high ex vivo migratory capacity. PDGFs,
via binding to their cognate receptors PDGFRα and
PDGFRβ, have been reported previously as potent che-
moattractants for multiple cell types including hBMSC
[47–50]. Our study corroborates and extends previous
findings by showing the possible prospective isolation of
hBMSC with enhanced migratory capacity based on
PDGFRβ expression.
Our study has some limitations. First, we employed a
telomerized cell line (hBMSC-TERT) and not primary
hBMSC for isolating subpopulations of BMSC. hBMSC-
TERT has the advantage of having a stable phenotype
during long-term culture and our extensive experience
with hBMSC-TERT demonstrate that these cells main-
tain a phenotype similar to primary hBMSC in vitro and
in vivo [24] and has comparable molecular signature to
primary hBMSC [51]. While hMSC-TERT has been
employed in a clinical trial as a vehicle for drug delivery
[52], the cells are not suitable for clinical trials for bone
regeneration due to their genetic modification and the
risk of transformation. Future studies on the relevance
of our findings to in vivo bone regeneration should thus
be conducted using primary human cells in preclinical
animal models [53]. Second, the identified PDGFRβ can
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be both a marker and functional protein contributing to
enhance migration. Our studies do not distinguish be-
tween these two possibilities. Third, prospective isolation
of PDGFRβ+ cells from heterogeneous hBMSC cultures
that can both home and contribute to fracture healing
needs to be performed.
Conclusion
This study demonstrates that cultured hBMSC, in
addition to cellular heterogeneity, exhibit functional het-
erogeneity and that bone formation and homing abilities
are closely linked characteristics that can be defined by a
common molecular signature. Further studies are needed
to determine the role of PDGFRβ in hBMSC homing and
to isolate hBMSC populations based on their molecular
signature to be tested in preclinical animal models for
enhancing fracture healing and bone regeneration.
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